Floatz logo

S-1

Pancreatic Ductal Adenocarcinoma

Genentech, Inc.UNKNOWNPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

279 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
OHSU Knight Cancer Institute
Phase 2BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Metformin
British Columbia Cancer Agency
Phase 2BB

View all 50 →

Same molecule, other indications

S-1 is also rated in:

malignant pancreatic neoplasmActive
BB
Indicative · Phase 4
68 / 100
View asset →
gastric neoplasmDormant
BB
Indicative · Phase 3
64 / 100
View asset →
colorectal neoplasmActive
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →